Stoke CMO sells 1,795 STOK shares in open trade

Stoke Therapeutics, Inc. Chief Medical Officer Barry Ticho reported an open-market sale of 1,795 shares of common stock at $30.58 per share.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. Chief Medical Officer Barry Ticho reported an open-market sale of 1,795 shares of common stock at $30.58 per share. After the transaction, he directly holds 34,826 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, indicating it was scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 1,795 shares

Net Sell 1 txn

Insider Ticho Barry

Role CHIEF MEDICAL OFFICER

Sold 1,795 shs ($55K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,795	$30.58	$55K

Holdings After Transaction: Common Stock — 34,826 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.

Key Figures

Shares sold: 1,795 shares Sale price per share: $30.58 per share Shares owned after sale: 34,826 shares +2 more

5 metrics

Shares sold 1,795 shares Open-market sale of common stock on 2026-06-01

Sale price per share $30.58 per share Average transaction price for sold shares

Shares owned after sale 34,826 shares Direct holdings following the transaction

Transaction code S Sale in open market or private transaction

Trading plan adoption date November 19, 2025 Date Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"reported on a Form 4 insider trading filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Stoke Therapeutics (STOK) disclose for Barry Ticho?

Stoke Therapeutics disclosed that Chief Medical Officer Barry Ticho completed an open-market sale of 1,795 shares of common stock at $30.58 per share. This was reported on a Form 4 insider trading filing with the U.S. Securities and Exchange Commission.

How many Stoke Therapeutics (STOK) shares does Barry Ticho hold after this Form 4 sale?

After the reported sale, Chief Medical Officer Barry Ticho directly holds 34,826 shares of Stoke Therapeutics common stock. This post-transaction balance is disclosed in the Form 4 as the total shares beneficially owned following the open-market sale.

Was the Barry Ticho stock sale in Stoke Therapeutics (STOK) pre-planned?

Yes. A footnote explains the transaction was executed under a Rule 10b5-1 trading plan adopted by Barry Ticho on November 19, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio management from discretionary timing decisions.

What was the price per share in Barry Ticho’s Stoke Therapeutics (STOK) stock sale?

The Form 4 reports that Barry Ticho’s sale of 1,795 Stoke Therapeutics common shares was executed at an average price of $30.58 per share. This price is listed as the transaction price per share for the open-market sale on the transaction date.

What type of transaction was reported in this Stoke Therapeutics (STOK) Form 4?

The filing describes the event as an open-market sale of non-derivative common stock, using transaction code “S.” This code indicates a sale in an open market or private transaction, rather than an option exercise, gift, tax withholding, or derivative-related transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		1,795	D	$30.58	34,826	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.

	/s/ Jonathan Allan, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)